may have noticed uh some of the pharmaceutical names have moved up sharply in the last few minutes. We've got some breaking news out of Washington on drug pricing. Aean Jabers has the details perhaps filling us in on why we've seen this move.Aean. Yeah, David. It is pharmaceutical related.Uh and we don't have all the details right now. We're trying to solve a mystery in real time here, which is that the president has an event on his calendar at 11:00 a. m.just scheduled as an announcement. Uh and the questi ...

U.S. President Donald Trump speaks during a press conference in the Roosevelt Room at the White House in Washington, D.C., U.S., May 12, 2025.President Donald Trump on Tuesday will announce an agreement with Pfizer to voluntarily sell its medications at lower prices, as his administration pushes to link U.S. drug prices to the cheaper prices paid abroad.Trump will announce a drug pricing deal with Pfizer at 11 a.m. ET, White House spokesperson Kush Desai said in a statement. Pfizer CEO Albert Bourla will be ...

公司业务概况 - 公司为全球医疗保健和生物制药企业 专注于疫苗、药物及消费者健康产品的研发与分销[3] - 疫苗产品组合超过20种 在疫苗、免疫学和呼吸治疗领域处于领先地位[3] - 癌症治疗药物覆盖多发性骨髓瘤、卵巢癌和子宫内膜癌等适应症[3] 财务表现 - 2025财年第二季度总销售额达80亿英镑[2] - 季度营业利润同比增长33% 每股收益增长35% 主要受益于CCL费用降低[2] - 经营活动产生现金24亿英镑 自由现金流达11亿英镑[2] 市场观点与估值 - 被列为50美元以下最佳成长股之一[1] - Kepler Capital维持持有评级 目标股价设定为1500便士[1] - 部分市场观点认为存在被低估可能性[2][4] 同业比较 - 分析机构认为人工智能板块股票可能提供更高上行潜力及更低下行风险[4] - 部分AI股票被指出可能受益于关税政策及本土化趋势[4]